<--- Back to Details
First PageDocument Content
Boceprevir / Biology / Pharmacology / Medicine / Hepatitis C / Hepatitis C and HIV co-infection / Interferon / Ribavirin / Nitazoxanide / Antivirals / Protease inhibitors / Hepatitis
Date: 2012-11-14 11:01:02
Boceprevir
Biology
Pharmacology
Medicine
Hepatitis C
Hepatitis C and HIV co-infection
Interferon
Ribavirin
Nitazoxanide
Antivirals
Protease inhibitors
Hepatitis

Best Practice/ Tool/Guideline

Add to Reading List

Source URL: globalhepc.files.wordpress.com

Download Document from Source Website

File Size: 144,11 KB

Share Document on Facebook

Similar Documents

Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study

DocID: 1vngt - View Document

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes   

DocID: 1vjI2 - View Document

Contact PD/PI: Braithwaite, Ronald Scott A. SPECIFIC AIMS Many persons with HIV have Hepatitis C (HCV) co-infection and consume alcohol.1,2 Now that highly effective and easily tolerated therapies for HCV are available,

DocID: 1vbzY - View Document

PRESS RELEASE AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection  TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C

DocID: 1vais - View Document